554 related articles for article (PubMed ID: 10509562)
1. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
Eagling VA; Profit L; Back DJ
Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
[TBL] [Abstract][Full Text] [Related]
3. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Lucia MB; Rutella S; Leone G; Vella S; Cauda R
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):321-30. PubMed ID: 11468419
[TBL] [Abstract][Full Text] [Related]
4. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.
Alsenz J; Steffen H; Alex R
Pharm Res; 1998 Mar; 15(3):423-8. PubMed ID: 9563072
[TBL] [Abstract][Full Text] [Related]
5. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Gupta A; Zhang Y; Unadkat JD; Mao Q
J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
[TBL] [Abstract][Full Text] [Related]
7. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
[TBL] [Abstract][Full Text] [Related]
8. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines.
Ronaldson PT; Lee G; Dallas S; Bendayan R
Pharm Res; 2004 May; 21(5):811-8. PubMed ID: 15180339
[TBL] [Abstract][Full Text] [Related]
9. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
[TBL] [Abstract][Full Text] [Related]
10. A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells.
Patel J; Hussain A; Pal D; Mitra AK
Am J Ther; 2004; 11(2):114-23. PubMed ID: 14999363
[TBL] [Abstract][Full Text] [Related]
11. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
[TBL] [Abstract][Full Text] [Related]
12. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.
Drewe J; Gutmann H; Fricker G; Török M; Beglinger C; Huwyler J
Biochem Pharmacol; 1999 May; 57(10):1147-52. PubMed ID: 11230802
[TBL] [Abstract][Full Text] [Related]
13. Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers.
Rouquayrol M; Gaucher B; Roche D; Greiner J; Vierling P
Pharm Res; 2002 Nov; 19(11):1704-12. PubMed ID: 12458677
[TBL] [Abstract][Full Text] [Related]
14. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.
Dupuis ML; Flego M; Molinari A; Cianfriglia M
HIV Med; 2003 Oct; 4(4):338-45. PubMed ID: 14525546
[TBL] [Abstract][Full Text] [Related]
15. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
Patel J; Buddha B; Dey S; Pal D; Mitra AK
Am J Ther; 2004; 11(4):262-77. PubMed ID: 15266218
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
[TBL] [Abstract][Full Text] [Related]
17. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
Perloff MD; von Moltke LL; Fahey JM; Daily JP; Greenblatt DJ
AIDS; 2000 Jun; 14(9):1287-9. PubMed ID: 10894301
[No Abstract] [Full Text] [Related]
18. Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
Schütt M; Zhou J; Meier M; Klein HH
J Endocrinol; 2004 Dec; 183(3):445-54. PubMed ID: 15590971
[TBL] [Abstract][Full Text] [Related]
19. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
20. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
